These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1526289)

  • 1. Chemoimmunotherapy of cancer: cyclophosphamide-resistant tumour cells are equally sensitive as the original tumour cell population to local IL-2 immunotherapy.
    Símová J; Bubeník J; Jandlová T
    Folia Biol (Praha); 1992; 38(2):122-8. PubMed ID: 1526289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
    Símová J; Bubeník J; Voitenok NN; Gren E
    Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E; Ben-Aziz R; Shiloni E
    Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E; Chriqui-Zeira E; Kyriazis AP
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM; Sugarbaker PH
    Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
    J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
    Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R; Kamdar SJ; Duffy T; Edison L
    J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
    Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
    J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.